PubRank

D N Louis

Author PubWeight™ 169.60‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001 6.78
2 Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998 5.30
3 Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol 2000 5.28
4 PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 2001 4.53
5 CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996 4.42
6 Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994 3.19
7 Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations (CCM1). Hum Mol Genet 1999 3.15
8 The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998 2.77
9 Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999 2.42
10 Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001 2.28
11 Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 1997 2.28
12 Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues. Lab Invest 1999 2.27
13 Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995 2.19
14 PTEN mutations in gliomas and glioneuronal tumors. Oncogene 1998 2.01
15 Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997 1.95
16 Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg 2000 1.82
17 Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993 1.67
18 Chronic lymphocytic leukemia and the central nervous system: a clinical and pathological study. Neurology 1996 1.66
19 Intramedullary cavernous angiomas of the spinal cord: clinical presentation, pathological features, and surgical management. Neurosurgery 1992 1.65
20 Exon scanning for mutation of the NF2 gene in schwannomas. Hum Mol Genet 1994 1.62
21 Familial schwannomatosis: exclusion of the NF2 locus as the germline event. Neurology 2003 1.57
22 Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol 2000 1.54
23 Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol 1999 1.52
24 Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989. Cancer 1994 1.52
25 Adult medulloblastoma: prognostic factors and patterns of relapse. Neurosurgery 2000 1.49
26 p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 1992 1.48
27 NHE-RF, a merlin-interacting protein, is primarily expressed in luminal epithelia, proliferative endometrium, and estrogen receptor-positive breast carcinomas. Am J Pathol 2001 1.47
28 Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res 1996 1.44
29 Molecular pathways in the formation of gliomas. Glia 1995 1.43
30 Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene 2006 1.41
31 Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am J Hum Genet 2001 1.39
32 A transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics 2000 1.39
33 Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 2001 1.38
34 The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol 1994 1.37
35 Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 1997 1.37
36 Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res 1992 1.33
37 Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 2000 1.32
38 Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol 1995 1.32
39 EHD2, EHD3, and EHD4 encode novel members of a highly conserved family of EH domain-containing proteins. Genomics 2000 1.31
40 Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas. Cancer Res 1994 1.29
41 Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci U S A 2001 1.29
42 Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg 1992 1.28
43 Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology 2009 1.27
44 Correlation of high-resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens. Cancer Res 1998 1.26
45 Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol 1998 1.24
46 Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas. Cancer Res 1994 1.20
47 Mutational analysis of patients with neurofibromatosis 2. Am J Hum Genet 1994 1.17
48 A rapid and non-radioactive PCR based assay for the detection of allelic loss in human gliomas. Neuropathol Appl Neurobiol 1993 1.17
49 Central neurocytomas of the cervical spinal cord. Report of two cases. J Neurosurg 1994 1.16
50 Selective inactivation of p53 facilitates mouse epithelial tumor progression without chromosomal instability. Mol Cell Biol 2001 1.16
51 A locus for cerebral cavernous malformations maps to chromosome 7q in two families. Genomics 1995 1.15
52 Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 1996 1.14
53 Human gliomas with wild-type p53 express bcl-2. Cancer Res 1995 1.11
54 Accumulation of wild type p53 protein in human astrocytomas. Cancer Res 1993 1.10
55 MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Mol Genet 1994 1.09
56 The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 1992 1.09
57 Developmental expression of the tuberous sclerosis proteins tuberin and hamartin. Acta Neuropathol 2001 1.06
58 Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. J Neurosurg 2000 1.06
59 Molecular genetic analysis of giant cell glioblastomas. Am J Pathol 1997 1.06
60 Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1. Neurology 2003 1.05
61 PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 2001 1.04
62 Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther 1998 1.04
63 A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications. J Clin Invest 1997 1.03
64 CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations. Am J Pathol 1998 1.03
65 Universal absence of merlin, but not other ERM family members, in schwannomas. Am J Pathol 1997 1.02
66 Deletion mapping of chromosome 19 in human gliomas. Int J Cancer 1994 1.01
67 Sentinel lesions of primary CNS lymphoma. J Neurol Neurosurg Psychiatry 1996 1.01
68 Primary lymphoma of peripheral nerve: report of four cases. Am J Surg Pathol 2000 1.00
69 Mapping of a target region of allelic loss to a 0.5-cM interval on chromosome 22q13 in human colorectal cancer. Gastroenterology 1999 1.00
70 Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices. J Neuropathol Exp Neurol 1996 0.99
71 Common regions of deletion on chromosome 22q12.3-q13.1 and 22q13.2 in human astrocytomas appear related to malignancy grade. J Neuropathol Exp Neurol 1999 0.98
72 The putative glioma tumor suppressor gene on chromosome 19q maps between APOC2 and HRC. Cancer Res 1994 0.97
73 Systemic metastasis in glioblastoma may represent the emergence of neoplastic subclones. J Neuropathol Exp Neurol 2000 0.97
74 p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab 1994 0.96
75 Amplification of the cyclin-dependent kinase 4 (CDK4) gene is associated with high cdk4 protein levels in glioblastoma multiforme. Acta Neuropathol 1996 0.95
76 Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A. Leukemia 2000 0.95
77 Meningioangiomatosis is associated with neurofibromatosis 2 but not with somatic alterations of the NF2 gene. J Neuropathol Exp Neurol 1997 0.95
78 Refined localization of the cerebral cavernous malformation gene (CCM1) to a 4-cM interval of chromosome 7q contained in a well-defined YAC contig. Genome Res 1995 0.94
79 Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma. Leukemia 1999 0.94
80 Multiple polymorphisms, but no mutations, in the WAF1/CIP1 gene in human brain tumours. Br J Cancer 1995 0.93
81 Case report of unusual leukoencephalopathy preceding primary CNS lymphoma. J Neurol Neurosurg Psychiatry 1998 0.92
82 A clinical study of patients with multiple isolated neurofibromas. J Med Genet 2001 0.92
83 Metastatic ependymoma of the sacrum. Cancer 1990 0.91
84 Gain of chromosome arm 1q in atypical meningioma correlates with shorter progression-free survival. Neuropathol Appl Neurobiol 2012 0.91
85 Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. Genes Chromosomes Cancer 2000 0.91
86 Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval. Oncogene 1996 0.91
87 Chromosome 19q deletions in human gliomas overlap telomeric to D19S219 and may target a 425 kb region centromeric to D19S112. J Neuropathol Exp Neurol 1995 0.90
88 Homozygous deletions of the CDKN2C/p18INK4C gene on the short arm of chromosome 1 in anaplastic oligodendrogliomas. Brain Pathol 1999 0.90
89 Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL. Brain Pathol 1998 0.90
90 Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas. J Neuropathol Exp Neurol 1997 0.90
91 The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. Cancer Genet Cytogenet 1996 0.89
92 Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors. Oncogene 2010 0.89
93 Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathol 1998 0.88
94 Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther 1998 0.88
95 Expression of NF2-encoded merlin and related ERM family proteins in the human central nervous system. J Neuropathol Exp Neurol 1997 0.88
96 Molecular genetic alterations in pleomorphic xanthoastrocytoma. Acta Neuropathol 1996 0.86
97 Familial occurrence of adiposis dolorosa. J Am Acad Dermatol 2001 0.85
98 Cloning of a highly conserved human protein serine-threonine phosphatase gene from the glioma candidate region on chromosome 19q13.3. Genomics 1995 0.85
99 General method for PCR amplification and direct sequencing of mRNA differential display products. Biotechniques 1995 0.85
100 The NF2 gene and merlin protein in human osteosarcomas. Neurogenetics 1998 0.85
101 Astrocytic gliomas: characterization on a molecular genetic basis. Recent Results Cancer Res 1994 0.85
102 Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol 1995 0.84
103 Loss of the NF2 gene and merlin occur by the tumorlet stage of schwannoma development in neurofibromatosis 2. J Neuropathol Exp Neurol 1998 0.83
104 Current treatment of oligodendrogliomas. Arch Neurol 1999 0.82
105 A novel splice site associated polymorphism in the tuberous sclerosis 2 (TSC2) gene may predispose to the development of sporadic gangliogliomas. J Neuropathol Exp Neurol 1997 0.82
106 NF2 gene analysis distinguishes hemangiopericytoma from meningioma. Am J Pathol 1995 0.82
107 Correction: central neurocytomas of the cervical spinal cord. J Neurosurg 1995 0.82
108 Deletions on the long arm of chromosome 17 in pilocytic astrocytoma. Acta Neuropathol 1993 0.82
109 ANOVA, a putative astrocytic RNA-binding protein gene that maps to chromosome 19q13.3. Neurogenetics 1997 0.81
110 The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor. Neurosurgery 1995 0.81
111 Mutation analysis of the hCHK2 gene in primary human malignant gliomas. Neurogenetics 2000 0.81
112 Chromosomal localization to 19q13.3, partial genomic structure and 5' cDNA sequence of the human symplekin gene. Somat Cell Mol Genet 1997 0.80
113 The human glia maturation factor-gamma gene: genomic structure and mutation analysis in gliomas with chromosome 19q loss. Neurogenetics 1999 0.80
114 In situ polymerase chain reaction demonstration of JC virus in progressive multifocal leukoencephalopathy, including an index case. Ann Neurol 1994 0.80
115 Up-regulation of specific NF 1 gene transcripts in sporadic pilocytic astrocytomas. Am J Pathol 1996 0.80
116 Development of a novel non-human primate model for preclinical gene vector safety studies. Determining the effects of intracerebral HSV-1 inoculation in the common marmoset: a comparative study. Gene Ther 2003 0.79
117 The APC gene in Turcot's syndrome. N Engl J Med 1995 0.79
118 Homozygous deletions of the CDKN2/p16 gene in dural hemangiopericytomas. Acta Neuropathol 1996 0.79
119 Assignment of the human gene encoding eukaryotic initiation factor 4E (EIF4E) to the region q21-25 on chromosome 4. Somat Cell Mol Genet 1997 0.78
120 Regional expression and subcellular localization of the tyrosine-specific phosphatase SH-PTP2 in the adult human nervous system. Neuroscience 1996 0.78
121 Histopathologic and immunohistochemical prognostic factors in malignant gliomas. Curr Opin Oncol 1997 0.78
122 Glioblastoma multiforme in four siblings: a cytogenetic and molecular genetic study. J Neurooncol 1995 0.78
123 Malignant solitary fibrous tumour of the meninges with marked amianthoid fibre deposition. Neuropathol Appl Neurobiol 2008 0.78
124 Chemosensitive gliomas in adults: which ones and why? J Clin Oncol 1997 0.78
125 Multicolumn infusion of gene therapy cells into human brain tumors: technical report. Neurosurgery 2000 0.78
126 Sarcomatous proliferation of the vasculature in a subependymoma: a follow-up study of sarcomatous dedifferentiation. Acta Neuropathol 1990 0.78
127 Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm. Cancer Gene Ther 1996 0.77
128 Third ventricular xanthogranulomas clinically and radiologically mimicking colloid cysts. Report of two cases. J Neurosurg 1994 0.77
129 Clear cell pleomorphic xanthoastrocytoma: case report. Acta Neuropathol 2001 0.76
130 Molecular genetics of radiographically defined de novo glioblastoma multiforme. Neuropathol Appl Neurobiol 2000 0.76
131 Analysis of the retinoblastoma tumour suppressor gene in pancreatic endocrine tumours. Clin Endocrinol (Oxf) 1997 0.76
132 The hPMS2 exon 5 mutation and malignant glioma. Case report. J Neurosurg 1999 0.75
133 Evidence for subarachnoid spread in the development of multiple meningiomas. Brain Pathol 1995 0.75
134 Bowlogenic dysrhythmias. Am J Med 1986 0.75
135 New approaches to the molecular biology, classification, and therapy of nervous system tumors: a workshop of the National Institutes of Health Pathology B study section. Am J Pathol 2001 0.75
136 Neurofibrillary tangles and olfactory dysgenesis. Lancet 1991 0.75
137 Spinal cord astrocytoma: response to PCV chemotherapy. Neurology 2000 0.75
138 The AgNOR technique, PCNA immunohistochemistry, and DNA ploidy in the evaluation of choroid plexus biopsy specimens. Am J Clin Pathol 1993 0.75
139 Images in clinical medicine. Acute bacterial meningitis. N Engl J Med 1994 0.75
140 Magnetic resonance imaging features of solitary inflammatory brain masses. J Neuroimaging 1998 0.75
141 Clinicopathologic correlation in a case of pupillary dilation from cerebral hemorrhage. Arch Neurol 1991 0.75
142 The brain stem viewed in situ from above. Arch Neurol 1992 0.75
143 Edward Peirson Richardson Jr (1918-1998) and the discovery of PML. J Neurovirol 1999 0.75
144 A new 1.9-mu wavelength laser for neurosurgery. J Neurosurg 1990 0.75
145 A RsaI polymorphism in the ERCC2 locus. Hum Mol Genet 1992 0.75
146 Accumulation of wild-type p53 in astrocytomas is associated with increased p21 expression. Acta Neuropathol 1997 0.75
147 Nucleolar organizer regions in optic gliomas. Brain 1993 0.75